Filing Details
- Accession Number:
- 0001209191-23-026270
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-01 16:26:35
- Reporting Period:
- 2023-04-27
- Accepted Time:
- 2023-05-01 16:26:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-04-27 | 1,611 | $338.69 | 128,358 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-27 | 1,668 | $339.43 | 126,690 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-27 | 38 | $340.19 | 126,652 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.
- Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99).
- Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98).
Billionaire Hedge Funds
